Narsoplimab
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
18
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA)
Conditions
Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA)
Trial Timeline
— → —
NCT ID
NCT04247906About Narsoplimab
Narsoplimab is a pre-clinical stage product being developed by Omeros Corporation for Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA). The current trial status is completed. This product is registered under clinical trial identifier NCT04247906. Target conditions include Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA).
Hype Score Breakdown
Clinical
5
Activity
2
Company
5
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04247906 | Pre-clinical | Completed |
Competing Products
20 competing products in Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA)